Ethical Safety Net Providers

2017 ◽  
Vol 77 (2) ◽  
pp. 309-309
Author(s):  
Robin Mathews
Keyword(s):  
Safety Net ◽  
Safety Net Providers

After the Affordable Care Act: Health Reform and the Safety Net

2016 ◽  
Vol 44 (4) ◽  
pp. 585-588
Author(s):  
Peter Shin ◽  
Marsha Regenstein
Keyword(s):  
Health Care ◽  
Community Health ◽  
Affordable Care Act ◽  
Health Reform ◽  
Community Health Centers ◽  
Safety Net ◽  
Public Hospitals ◽  
Health Centers ◽  
Safety Net Providers ◽  
The Affordable Care Act

Two major safety net providers – community health centers and public hospitals – continue to play a key role in the health care system even in the wake of coverage reform. This article examines the gains and threats they face under the Affordable Care Act.

Characteristics of Primary Care Safety-Net Providers and Their Quality Improvement Attitudes and Activities

2012 ◽  
Vol 28 (2) ◽  
pp. 151-159 ◽  
Author(s):  
Lenny López ◽  
Catherine M. DesRoches ◽  
Christine Vogeli ◽  
Richard W. Grant ◽  
Lisa I. Iezzoni ◽  
...  
Keyword(s):  
Primary Care ◽  
Quality Improvement ◽  
Safety Net ◽  
Safety Net Providers

scholarly journals Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals

2012 ◽  
Vol 3 (1) ◽  
Author(s):  
Madeline Carpinelli Wallack ◽  
Todd Sorensen
Keyword(s):  
Federal Government ◽  
Orphan Drug ◽  
Orphan Drugs ◽  
Safety Net ◽  
Original Research ◽  
Critical Access Hospitals ◽  
Patient Protection ◽  
High Prevalence ◽  
Safety Net Providers ◽  
The Impact

Purpose: The 340B Drug Pricing Program is a federal program designed to reduce the amount that safety net providers spend on outpatient drugs. The Patient Protection and Affordable Health Care Act of 2010 extended eligibility for 340B to critical access hospitals (CAHs) for all drugs except those designated as "orphan." Because this policy is unprecedented, this study quantifies the gross financial impact that this exemption has on a group of CAHs. Methods: Drug spending for 2010 from 18 CAHs in Minnesota and Wisconsin are reviewed to identify the prevalence of orphan drug purchases and to calculate the price differentials between the 340B price and the hospitals' current cost. Results: The 18 CAHs' purchases of orphan drugs comprise an average of 44% of the total annual drug budgets, but only 5% of units purchased, thus representing a very high proportion of their expenditures. In the aggregate, the 18 hospitals would have saved $3.1 million ($171,000 average per hospital) had purchases of drugs with orphan designations been made at the 340B price. Because CAH claims for Medicare are reimbursed on a cost-basis, the Federal government is losing an opportunity for savings. Conclusion: The high prevalence of orphan drug use and considerable potential for cost reduction through the 340B program demonstrate the loss of benefit to the hospitals, Federal government and the states.   Type: Original Research

Uneasy Alliances: Managed Care Plans Formed By Safety-Net Providers

2000 ◽  
Vol 19 (4) ◽  
pp. 23-35 ◽  
Author(s):  
Michael S. Sparer ◽  
Lawrence D. Brown
Keyword(s):  
Managed Care ◽  
Safety Net ◽  
Care Plans ◽  
Safety Net Providers
Sign in / Sign up

Export Citation Format

Share Document